SABRA HEALTH CARE REIT, INC.
At today's price, SABRA HEALTH CARE REIT, INC. (SBRA) is priced for -4.2% FFO growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- At about $18.12 the trust trades near 14x adjusted funds from operations, a multiple so low the price sits below what even a 5%-a-year decline in funds from operations would warrant. The price is pricing erosion, not the growth the recent quarter showed. - The watch item is leverage and operator credit: net debt about 7.3x funds from operations with fixed-charge coverage of 4.1x, on a portfolio that has been shifting toward private-pay senior housing and away from skilled nursing.
Is SBRA overvalued? See what's priced in →
444 institutional managers reported holding SBRA in 13F filings for the quarter ended 2026-03-31. 61 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 26.5M shares were sold short as of the 2026-06-15 count, about 10% of shares outstanding (7.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
SBRA's share count grew 16.6% over the past five years. It pays a dividend, and has paid one every year in our records (15 and counting); the current rate is $1.20 a share annually. Cash returned over the past three years: $784.04M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at SBRA over the trailing three years: 2023: 1 buy totaling $25k; 2024: 1 buy totaling $101k; 2025: 2 buys totaling $40k. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
SBRA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | +0.8% | +10.4% |
| 2023-11-07 | +0.7% | -1.8% |
| 2024-02-28 | +0.4% | -0.5% |
| 2024-05-09 | -1.7% | +7.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
SBRA's latest 8-K filings: 2026-06-17 (items 5.07); 2026-05-28 (items 7.01, 9.01); 2026-04-29 (items 2.02, 7.01, 9.01); 2026-02-12 (items 2.02, 7.01, 9.01); 2026-01-05 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.